Evidence map›Paper›PMID 41691435›Full record

ArticleAdvanced healthcare materials2026

Taming the Immiscibility of Gold, Iron, and Boron to Craft Chemodegradable Nanoparticles for Multimodal Imaging and Radiotherapy.

Michael Bissoli, Clara M G de Faria, Veronica Torresan, Maria Assunta Lacavalla, Mattia Cattelan, Denis Badocco, Paolo Pastore, Pasquina Marzola, Laura Cansolino, Cinzia Ferrari and 6 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Michael BissoliDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Clara M G de FariaDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Veronica TorresanDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Maria Assunta LacavallaDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Mattia CattelanDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Denis BadoccoDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Paolo PastoreDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Pasquina MarzolaDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.
Laura CansolinoDepartment of Clinical Surgical Sciences, Integrated Unit of Experimental Surgery, Advanced Microsurgery and Regenerative Medicine, University of Pavia, Pavia, Italy.
Cinzia FerrariDepartment of Clinical Surgical Sciences, Integrated Unit of Experimental Surgery, Advanced Microsurgery and Regenerative Medicine, University of Pavia, Pavia, Italy.
Ian PostumaINFN (National Institute of Nuclear Physics), Unit of Pavia, Pavia, Italy.ORCID https://orcid.org/0000-0001-9678-9277
Riccardo VagoUrological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Silva BortolussiINFN (National Institute of Nuclear Physics), Unit of Pavia, Pavia, Italy.
Antonello E SpinelliExperimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Daniel ForrerDepartment of Chemical Sciences, University of Padova, Padova, Italy.
Vincenzo AmendolaDepartment of Chemical Sciences, University of Padova, Padova, Italy.ORCID https://orcid.org/0000-0002-9937-7005

Funding

AIRCFondazione AIRC per la ricerca sul cancro ETS MFAG 2021 - ID. 25681Università degli Studi di Padova MSCA Seal of Excellence @ UNIPD 2023 grant NANOXRT
6 · The paper itself

Abstract

Despite more than half of all oncological patients undergo X-ray radiotherapy (XRT), significant efforts are required to improve its efficacy against hypoxic tumor regions and, at the same time, to expand the therapeutic window to spare normal tissues. The use of radiosensitizers, the personalization of radiation dose planning aided by imaging with magnetic resonance imaging (MRI) and X-ray computed tomography (CT), and the implementation of boron neutron capture therapy (BNCT) are three strategies to encompass the limits of XRT. Here, these three strategies are leveraged by designing and achieving a theranostic platform based on trimetallic Au-Fe-B nanoparticles (NPs). According to density functional theory calculations, chemodegradable Au-Fe-B nanostructures are not achievable under thermodynamic equilibrium conditions. Hence, Au-Fe-B NPs were synthesized by laser ablation in liquid, because it is a nonequilibrium process, followed by a tailored cleaning protocol. The Au-Fe-B NPs were coated with biocompatible polymers and showed several useful properties for nanomedicine application, such as chemical degradation in a physiological environment, contrast ability for MRI and CT, in vitro radiosensitization efficacy for XRT and BNCT, and consistent intracellular uptake. These functionalities can enable advanced studies on tumor treatment with complementary therapeutic strategies guided by anatomic imaging, leading to more effective oncological protocols.

Indexed as

BoronGoldIronMetal NanoparticlesMultimodal ImagingAnimalsBoron Neutron Capture TherapyCell Line, TumorHumansMagnetic Resonance ImagingRadiation-Sensitizing AgentsBoronGoldIronRadiation-Sensitizing AgentsDFTimaginglaser ablationnanoalloysradiotherapy

Identifiers

PMID41691435
PMCPMC13107933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.